Public company info - Bloomage BioTechnology Corporation Ltd. , 00963.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Bloomage BioTechnology Corporation Ltd., 00963.HK - Company Profile
Chairman Zhao Yan
Share Issued (share) 366,000,000
Par Currency Hong Kong Dollar
Par Value 0.01
Industry Medicine
Corporate Profile Business Summary: The Group is principally engaging in the manufacture and sale of bio-chemical products and trading of cosmetic products and medical devices and design, development, manufacturing and sales of cosmetic products. Performance for the year: The Group’s revenue for the year ended 31 December 2016 amounted to approximately RMB844.388 million, representing an increase of approximately 29.7% compared with the corresponding period in 2015. Profit attributable to equity shareholders of the Company increased by approximately 19.8% from approximately RMB190.393 million for the year ended 31 December 2015 to approximately RMB228.101 million for the year ended 31 December 2016. BUSINESS REVIEW In 2016, the Group remained stable growth amid fierce market competition, and further moved forward to become a medical aesthetics solutions provider. Capitalizing on its advantages in resources and platform, the Group focused on traditional HA raw material business, while continued to expand higher value end product business with HA as its core. We co-operated with domestics and overseas technologies and brands, and took customer experience as our fundamental concern, relentlessly developing us as an international enterprise with a variety of products of different brands which can be purchased from various channels. The market competition has been intensified in this year, however, through early deployment and resources optimization, both HA raw material and end product business of the Group recorded satisfactory results. HA raw materials business continued to expand in overseas market and realized an annual sales of approximately RMB458,015,000, representing an increase of approximately 15.4% compared with the corresponding period in 2015. The end product business has continued to transform into a multi-products solutions provider with an annual sales of approximately RMB294,786,000, representing an increase of approximately 21.1% compared with the corresponding period in 2015. With respect to trading business, the Group co-operated with overseas renowned brands to explore Asia market with an annual sales of approximately RMB91,587,000. With respect to raw material business, the Group vigorously prepared for our exploration into overseas medical HA markets. Relevant registration certificates were obtained in several countries and cooperative relationship with internationally renowned pharmaceutical companies was formed, strengthening the development in overseas market. The Group leveraged on professional fermentation technology platform to innovate and launch a series of new products based on HA, satisfying the demand of customer at multi-level while effectively enhancing our competitiveness. Facing rapid development in medical aesthetics market and more intense market competition, the Group continued to invest in corresponding resources to enrich our product portfolio and launch more medical aesthetics solutions with an aim to ensure a stable growth of our end product business. Despite adverse effects from the increased competition and price reduction pressure on the sales of HA injection fillers (BioHyalux), continuous optimization of Bio-MESO product lines and successful development of HA+ medical skin care product business have strongly underpinned further advancement of our entire end product business. Research & development and innovation have been the most significant driver of our development. At the end of this year, several products have obtained different milestone results in respect of technology development, clinical trial and product filing, it is expected that it will provide beneficial support to our future business expansion. Prospects: In 2017, the economic condition and the competition of medical aesthetics industry in the PRC will further intensify. The Group will implement a medical aesthetics ecological chain strategy by providing greater product portfolio and solution with a focus on customer experience. The Group will optimize the organizational structure and enhance the execution capability of its team. Facing with the characteristics of fast upgrade and regeneration as well as the unregulated competition of medical aesthetics industry, the Group will also accelerate the change in the development pace with innovation and diversification to strive for sustainable growth. Raw material product business The Group will continue to take HA as the core raw material and diversify HA’s traditional applications by vigorous exploration of domestic and international markets of medical-grade HA and opening new areas of HA applications. Leveraging on professional R&D platform and production technology of fermentation, the Group will strengthen the R&D and marketing of non-HA fermental products and their derivative products, striving to achieve medium- and long-term sustained and steady growth of the Group’s raw materials business segment. End product business The market demand for medical aesthetics in China continues to expand. Meanwhile, as the market matures, the fierce industry competition is also intensifying. In 2017, the sales of HA injectable filler products will still face difficulties and challenges. The Group will continue to develop the marketing strategy supported by skin care product portfolio, keep track of the medical aesthetic development trend, strengthen product and service innovation with a focus on customer to provide the industry with more precise services and business options. The Group will continue to promote the clinical registration of various domestic and imported brands of HA injectable filler to cope with more fierce competition and more refined demands from consumer groups. In 2017, the Group will strengthen the construction of the sales team, reinforce market positioning and brand segmentation of BioHyalux and Dermallure, and carry out accurate marketing and sales of product combo in collaboration with other skincare treatments to consolidate its market share of HA injectable filler. In 2017, the Group will further develop and expand the BACT (biological activated combined treatment) project as well as medical skincare business to create more skin beauty solution and medical skincare products with a focus on HA benefiting from the full launch of the CYTOCARE series of Revitacare France, whose entire equity interest was acquired by the Group in January 2017, the Group will redefine the breadth of skin beauty, from facial skin to body skin and then to scalp skin, so as to comprehensively meet the ultimate demand for beauty from consumers. The Bloomage Academy will also launch trainings for the use of HA products and related equipment for skin in different parts of the body. In 2017, the Group will strengthen consumer education and brand concepts cultivation by focusing more on the demand from consumers, pay more attention to consumer experience, and launch more skincare products to cater for consumers’ demands. Trading business The Group expects that in the next two years it will successively obtain the access approval for the Stylage series of facial injectable products of Vivacy and the series of products of Revitacare in more countries and regions in Asia. The Group will achieve steady growth in trading business by enhancing investment in market promotion through running various marketing activities jointly with local distributors to introduce new technologies and new application concepts to local medical aesthetics institutions.

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.